Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia.
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia (CLL).
There are currently 3 large registration trials exploring idelalisib, Brown states. One of these trials, a phase III study combining idelalisib with rituximab for patients with previously treated CLL, was halted early due to a high-level of efficacy in an interim analysis conducted by an external Data Monitoring Committee.
The median progression-free survival (PFS) for patients treated with idelalisib plus rituximab has not yet been reached. For rituximab plus placebo, the median PFS was 5.5 months. At the 24-week analysis of the trial, the PFS rate was 93% compared to 46%, for idelalisib and placebo, respectively.